icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
Oct 19, -23 2022
Washington DC

Back grey_arrow_rt.gif
 
 
 
A Case Series of Lo-Level HBV Viremia After Switching to Long-Acting Injectable Cabotegravir/Rilpivirine in Patients with HIV, Hepatitis B Core Antibody Positivity, and Hepatitis B Surface Antigen Negativity
 
 
 

1026221

1026222

1026223

1026224